Oxygen-independent real-time monitoring of distinct biphasic glutamate release using dialysis electrode in rat striatum during anoxia: in vivo evaluation of glutamate release and reversed uptake.
Using a dialysis electrode, previous studies showed a clear biphasic release of glutamate during anoxia and ischemia. In this study, we examined two hypotheses: (1) glutamate is of vesicular origin and its release is thus Ca2+- and ATP-dependent in the first phase, while in the second phase glutamate is derived primarily from the metabolic pool, and (2) reversed glutamate uptake, due to electrogenic stoichiometry, produces the second phase during anoxic insult in the rat brain. A dialysis electrode continuously perfused with glutamate oxidase and ferrocene-conjugated bovine serum albumin (BSA) optimized the time resolution of monitoring, allowing quantitative oxygen-independent, real-time measurement of the extracellular glutamate concentration ([Glu]e) during anoxia. [Glu]e dynamics were analyzed during anoxia by combining the dialysis electrode with focal microinjection of substances inducing glutamate release. Following anoxia in the rat brain, a sharp and rapid [Glu]e elevation took place (first phase). The [Glu]e elevation then shifted, continuing a gently sloping rise throughout the anoxic period (second phase). This first phase disappeared with intracranial administration of either Co2+ or omega-conotoxin. The second phase rise increased with focal microinjection of KCl (300 mM, 1 microL) and decreased with NaCl (300 mM, 1 microL), ultimately reaching a plateau in both cases. Preloading with a novel glutamate transporter inhibitor (tPDC) decreased both the first and second phases of [Glu]e elevation. This dialysis electrode system provides data supporting in vivo evidence that the peak of the first phase of [Glu]e elevation is derived from the "neurotransmitter pool," while the second phase is derived from the neuronal and glial "metabolic pool," which is, at least, partly related to a "reversed uptake" mechanism in the anoxic rat brain.
Asai
S
S
Department of Pharmacology, Nihon University School of Medicine, Itabashi, Tokyo, Japan. satoshi@med.nihon-u.ac.jp
Kohno
T
T
Katayama
Y
Y
Iribe
Y
Y
Hosoi
I
I
Kanematsu
K
K
Kunimatsu
T
T
Ishikawa
K
K
D000818:Animals; D003035:Cobalt / Q000494:pharmacology; D003199:Computer Systems; D003342:Corpus Striatum / Q000378:metabolism*; D003956:Dialysis / Q000295:instrumentation; D003998:Dicarboxylic Acids / Q000494:pharmacology; D004566:Electrodes; D005110:Extracellular Space / Q000378:metabolism; D018698:Glutamic Acid / Q000378:metabolism*; D000860:Hypoxia / Q000378:metabolism*; D007477:Ions; D008297:Male; D008845:Microinjections; D010100:Oxygen / Q000502:physiology; D011188:Potassium / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012964:Sodium / Q000494:pharmacology; D020866:omega-Conotoxin GVIA / Q000494:pharmacology
D003998:Dicarboxylic Acids; D007477:Ions; D011759:Pyrrolidines; D003035:Cobalt; D018698:Glutamic Acid; D011189:Potassium Chloride; D020866:omega-Conotoxin GVIA; C083486:pyrrolidine-2,4-dicarboxylic acid; D012964:Sodium; D011188:Potassium; D010100:Oxygen